In Vitro Activity of Lefamulin Against a Global Collection of Bacterial Pathogens Commonly Causing Community-Acquired Bacterial Pneumonia (CABP, SENTRY 2015)

BACKGROUND: CABP is the number one reason for death by infectious diseases worldwide and emerging resistance complicates its treatment. Lefamulin is the first semi-synthetic pleuromutilin antibiotic for IV and oral use in humans. It is currently in Phase 3 trials for the treatment of CABP in adults....

Descripción completa

Detalles Bibliográficos
Autores principales: Paukner, Susanne, Sader, Helio S, Streit, Jennifer M, Flamm, Robert K, Gelone, Steven P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631057/
http://dx.doi.org/10.1093/ofid/ofx163.916

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631057/
http://dx.doi.org/10.1093/ofid/ofx163.916

Ejemplares similares